Immunome, Inc. · NASDAQ:IMNM
Immunome — Investor Presentation (March 2021)
30 slides from Immunome's investor presentation, Mar 29, 2021
Slide 1: Harnessing the Human Memory B Cell Response To Develop Antibody-Based Therapeutics
Copyright © 2021 Immunome, Inc. All rights reserved. Harnessing the Human Memory B Cell Response To Develop Antibody - Based Therapeutics March 29, 2021 Immunome, Inc. 665 Stockton Drive, Suite 300 | Exton, PA 19341 610.321.3700 | www.immunome.com
Slide 2: Forward Looking Statements
2 Copyright © 2021 Immunome, Inc. All rights reserved. Forward Looking Statements This presentation includes certain disclosures that contain “forward - looking statements” intended to qualify for the “safe harbor” from liability established by the Private Securities Litigation Reform Act of 1995, a
Slide 3: Immunome Overview
Copyright © 2021 Immunome, Inc. All rights reserved. 3 Immunome Overview Harness the Power of the Most Educated Components of the Human Immune System • Rapid and unbiased interrogation of memory B cells to identify novel targets and antibodies directed at them • Output has potential to advance 1 - 2
Slide 4: The Power of Memory B Cells
Copyright © 2021 Immunome, Inc. All rights reserved. 4 The Power of Memory B Cells Immunome’s Discovery Engine Sees Disease Through the Lens of the Human Memory B Cell • Memory B cells remember specific antigens and allow for a rapid antibody response 1 • The antibodies that these cells produce are
Slide 5: Immunome Discovery Engine
Copyright © 2021 Immunome, Inc. All rights reserved. 5 Immunome Discovery Engine Unbiased Interrogation of Memory B Cells Yields a Deep and Diverse Set of Potential Therapies • Primary human memory B cells immortalized as stable hybridomas - thousands of hybridomas per patient • High - throughput sc
Slide 6: Using the B Cell Lens
Copyright © 2021 Immunome, Inc. All rights reserved. 6 Using the B Cell Lens Discovery Engine Appears to Reveal Rare and Novel Targets • Rare, broadly conserved epitopes in infectious disease » Antibodies binding to Spike protein epitopes conserved across multiple SARS - CoV - 2 variants and even SA
Slide 7: Immunome Pipeline & Anticipated Milestones
7 Copyright © 2021 Immunome, Inc. All rights reserved. Immunome Pipeline & Anticipated Milestones ONCOLOGY TARGET PRODUCT CANDIDATE DESCRIPTION DISCOVERY PRECLINICAL NEXT MILESTONE IMM - ONC - 01 IL - 38 I/O, Novel Checkpoint Anticipate IND filing 2H 2021 ANTI - INFECTIVES TARGET PRODUCT CANDIDATE D
Slide 8: Oncology Research & Development
Copyright © 2021 Immunome, Inc. All rights reserved. 8 Oncology RESEARCH & DEVELOPMENT
Slide 9: Untapped Potential in Immuno-Oncology
Copyright © 2021 Immunome, Inc. All rights reserved. 9 Untapped Potential in Immuno - Oncology Current Therapies are Based on Limited Understanding of the Diversity and Complexity of Human Tumors T cell targeted immuno - oncology approaches have redefined the way we treat cancer However, large numbe
Slide 10: Immunome's Discovery & Output
Copyright © 2021 Immunome, Inc. All rights reserved. 10 Immunome’s Discovery & Output Memory B Cells Interrogation Reveals Target Rich “Clusters” • Common biological processes that may have disease relevance, such as exosome control of the tumor microenvironment 1 - 2 • Novel immune checkpoints that
Slide 11: IL-38: A Novel Oncology Target
Copyright © 2021 Immunome, Inc. All rights reserved. 11 IL - 38: A Novel Oncology Target IL - 38 Appears to Dampen Innate Anti - Tumor Immunity • IL - 38 is an IL - 1 cytokine family member, but most closely resembles the natural antagonists of the family (IL - 1Ra and IL - 36a) • IL - 38 inhibits i
Slide 12: IL-38 Expression in Solid Tumors
Copyright © 2021 Immunome, Inc. All rights reserved. 12 IL - 38 Expression in Solid Tumors IL - 38 is Over - Expressed in Multiple Tumors of High Unmet Medical Need, and Associated with Reduced Immune Cell Infiltration IL - 38 is over - expressed in multiple tumors of high unmet medical need Inverse
Slide 13: Clinical Consequences of IL-38 Expression
Copyright © 2021 Immunome, Inc. All rights reserved. 13 Clinical Consequences of IL - 38 Expression Recent Literature Reports Show Correlation Between IL - 38 and Tumor Growth IL - 38 high IL - 38 low
Slide 14: IL-38 & Innate Immunity
Copyright © 2021 Immunome, Inc. All rights reserved. 14 IL - 38 & Innate Immunity IL - 38 Inhibits Myeloid Cell Activation In Vitro Blocks IL - 36 mediated inflammatory signals IL - 36 γ induced IL - 8 in PBMCs PNAS 2012;109 (8):3001 Suppresses Dendritic Cell Function Inhibits macrophage inflammator
Slide 15: IMM-ONC-01 Blocking IL-38 Leads to Tumor Control in Two Tumor Models
Copyright © 2021 Immunome, Inc. All rights reserved. 15 IMM - ONC - 01 Blocking IL - 38 Leads to Tumor Control in Two Different Tumor Models Demonstration of Anti - Tumor Activity (B16F10 Model) Induction of Anti - Tumor Memory (EMT6 Model) • Immunologically cold tumor model • IMM - ONC - 01 equival
Slide 16: IMM-ONC-01 Program Summary
Copyright © 2021 Immunome, Inc. All rights reserved. 16 IMM - ONC - 01 Program Summary Modulating Innate Anti - Tumor Immunity • IL - 38 is a novel checkpoint in the innate immune system » Target of an antibody isolated from the memory B cells of a patient with head and neck cancer • Targeting IL -
Slide 17: Infectious Diseases Research & Development
Copyright © 2021 Immunome, Inc. All rights reserved. 17 Infectious Diseases RESEARCH & DEVELOPMENT
Slide 18: Ongoing Need for COVID Therapies
Copyright © 2021 Immunome, Inc. All rights reserved. 18 Ongoing Need for COVID Therapies Our Hypothesis: Natural Viral Mutation, Selection Pressure of Interventions Expected to Drive Emergence of New Variants and Need for Novel Therapies Evolving SARS - CoV - 2 Escape Mutants • Efficacy of vaccines
Slide 19: IMM-BCP-01 Therapeutic Antibody Cocktail Against Multiple SARS-CoV-2 Antigens
Copyright © 2021 Immunome, Inc. All rights reserved. 19 IMM - BCP - 01 Therapeutic Antibody Cocktail Against Multiple SARS - CoV - 2 Antigens Collaboration with U.S. DoD awarded, up to $13.3M in funding Select convalescent patients with strong anti - viral titer Antibody cocktail for potential proph
Slide 20: IMM-BCP-01 Hypothesis
Copyright © 2021 Immunome, Inc. All rights reserved. 20 IMM - BCP - 01 Hypothesis Neutralizing Antibody Therapeutics vs. Immunome’s Antibody Cocktail Approach Neutralizing Antibodies • Target single protein • New strains may readily evade IMM - BCP - 01 Profile ▪ Multiple antibodies against diverse
Slide 21: B Cell Interrogation of Super-Responders
Copyright © 2021 Immunome, Inc. All rights reserved. 21 B Cell Interrogation of Super - Responders “Super Responders” Mount Robust Immune Response Against SARS - CoV - 2 More than 50% of the antibodies identified bind to SARS - CoV - 2 proteins other than Spike • Open Reading Frame - coded (ORF) pro
Slide 22: Anti-Spike Antibodies
Copyright © 2021 Immunome, Inc. All rights reserved. 22 Anti - Spike Antibodies Super Responders Express Broadly Neutralizing Anti - Spike SARS - CoV - 2 Antibodies • Antibodies identified against non - overlapping regions of SARS - CoV - 2 Spike protein » Includes regions containing critical mutati
Slide 23: IMM-BCP-01 Program Summary
Copyright © 2021 Immunome, Inc. All rights reserved. 23 IMM - BCP - 01 Program Summary Antibody Cocktail Targeting the Multiple SARS - CoV - 2 Antigens • Patients mount immune response against multiple SARS - CoV - 2 antigens • Certain anti - Spike antibodies neutralize multiple SARS - CoV - 2 varia
Slide 24: Summary
Copyright © 2021 Immunome, Inc. All rights reserved. 24 Summary SUMMARY
Slide 25: Immunome Pipeline & Anticipated Milestones
25 Copyright © 2021 Immunome, Inc. All rights reserved. ONCOLOGY TARGET PRODUCT CANDIDATE DESCRIPTION DISCOVERY PRECLINICAL NEXT MILESTONE IMM - ONC - 01 IL - 38 I/O, Novel Checkpoint Anticipate IND filing 2H 2021 ANTI - INFECTIVES TARGET PRODUCT CANDIDATE DESCRIPTION DISCOVERY PRECLINICAL NEXT MILE
Slide 26: Immunome: Harnessing the Power of the Most-educated Components of the Human Immune System
Copyright © 2021 Immunome, Inc. All rights reserved. 26 Immunome Harnessing the Power of the Most - educated Components of the Human Immune System • Proprietary Discovery Engine enables the interrogation of human memory B cells to simultaneously identify potential first - in - class antibody therape
Slide 27: Appendix
Copyright © 2021 Immunome, Inc. All rights reserved. 27 Appendix APPENDIX
Slide 28: Management Team
Copyright © 2021 Immunome, Inc. All rights reserved. 28 Management Team Michael Morin, PhD Chief Science Officer Oversaw cancer, immunology and anti - bacterial drug discovery Dennis Giesing , PhD Chief Development Officer Jillian DiMuzio Senior Director, HTS & Automation Ben Harman, PhD Director, T
Slide 29: Scientific Advisory Board
Copyright © 2021 Immunome, Inc. All rights reserved. 29 Scientific Advisory Board Scott Dessain, MD, PhD Chair, Founder Joseph and Ray Gordon Chair of Clinical Oncology and Research at Lankenau Institute for Medical Research George Prendergast, PhD Cancer Biology Former Editor of Cancer Research Pre
Slide 30: Board of Directors
Copyright © 2021 Immunome, Inc. All rights reserved. 30 Board of Directors Michael Rapp, Chairman Managing Partner, Broadband Capital Investments, LLC Richard Baron Formerly Chief Financial Officer, Zynerba Pharmaceuticals John LaMattina, PhD Formerly President, Pfizer Global Research & Development